Inside Precision Medicine July 17, 2024
Scorpion Therapeutics has closed a $150 million series C to support development of its precision oncology pipeline, including lead compound STX-478—a highly specific PI3Kα inhibitor. The financing was co-led by Frazier Life Sciences and Lightspeed Venture Partners and included additional new support from Willett Advisors and leading healthcare institutional investors, along with existing investors.
In particular, Scorpion plans to use the funds to expand clinical development of its allosteric, differentiated, mutant-selective PI3Kα inhibitor, STX-478, which is first being tested in breast cancer and other solid tumors. Further, the Company will continue to advance its clinical-stage EGFR inhibitor franchise, including STX-721 and STX-241, and its discovery pipeline of next-generation precision oncology therapies.
“The robust demand for this capital raise is a...
Today's Sponsors
Today's Sponsor